angiotensin receptor blockers (ARBs) - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 0.57 [0.18, 1.79]< 10%1 study (1/-)83.3 %NAnot evaluable crucial-
deaths 0.45 [0.08, 2.60]< 10%1 study (1/-)81.4 %NAnot evaluable crucial-
hospital discharge 2.15 [1.18, 3.93]> 10%1 study (1/-)99.4 %NAnot evaluable important-
mechanical ventilation 0.30 [0.03, 3.01]< 10%1 study (1/-)84.6 %NAnot evaluable important-
ICU admission 0.73 [0.18, 2.97]< 10%1 study (1/-)66.8 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.